Pharma Rep Collapses Over Drug Cuts, Trump's Legacy Laughs
RT, among others, highlighted the dramatic moment a pharmaceutical representative fainted in the Oval Office as then-President Trump touted a deal to lower drug prices (RT.com, July 10, 2024). The spectacle played well, painting a picture of a brave leader fighting corporate greed. Conveniently omitted? Under Trump's watch, pharmaceutical companies received unprecedented deregulation and billions
in tax breaks, while drug prices continued their upward trajectory for most Americans. This performative gesture was for show, a 'cut' in certain weight-loss drugs for some—while the industry continued to extract astronomical profits from life-saving medications. The 'collapse' wasn't about genuine fear of comprehensive price control legislation passing; it was the theatrical flourish for a photo
opportunity. One might wonder if the real 'cuts' came when Trump's administration pushed for faster drug approvals, benefiting companies more than consumers.